INTRODUCTION -- TCR-GENE TRANSFER FROM BENCH TO BEDSIDE
=======================================================

As an integral part of the adaptive immune system, T-cells have been attributed several protective functions directed against both microbial pathogens and tumor cells. Although derived from the self, neoplastic cells often express tumor antigens that can discriminate them from normal tissues and can be recognized by the adaptive immune system ([@B96]). Indeed, T lymphocytes demonstrate the capacity to eradicate cancer cells and a growing body of studies has shown that the adoptive cell transfer (ACT) of tumor-specific T lymphocytes ([@B53]; [@B108]) isolated from the tumor itself has been demonstrated to mediate impressive tumor regression in advanced melanoma patient, with almost a quarter of the treated individuals durable complete responders ([@B113]). Clinical trials based on adoptive T-cell transfer have been conducted in the last two decades for the treatment of viral conditions ([@B41]; [@B13]), especially in the context of bone marrow transplantation. Initially targeting cytomegalovirus (CMV; [@B157]), this strategy has been extended to other viruses such as Epstein--Barr virus (EBV; [@B56]), adenoviruses ([@B36]), and multiple viruses simultaneously ([@B77]).

Still, the isolation of such antigen-specific T-cells is not always possible and as such, alternative approaches have been designed to enable the generation of antigen-specific lymphocytes from peripheral T-cells. T lymphocytes can recognize their cognate antigen through the binding of their T-cell receptor (TCR) to an epitope presented by major histocompatibility complex (MHC) molecules on the target cells ([@B155]). This implies that the TCR dictates the specificity of a given T-cell and that it should prove feasible to provide T-cells with new specificities by transferring the genes of a given TCR. The successful reprogramming of T-cell specificity by TCR-gene transfer was first demonstrated by Steinmetz and colleagues in a murine system ([@B32]). Originally, the purpose of this report was to study the receptor dynamics, but it opened a novel field of therapeutic research dealing with gene-mediated redirection of T-cell specificity. This approach was then applied to endow T-cells with tumor specificity using a melanoma-specific TCR *in vitro* ([@B25]), and subsequently *in vivo*, using an influenza virus-specific receptor ([@B71]).

Basically, this strategy relies on the isolation of the genes encoding the α and β chains of a TCR specific for an antigen from a T-cell clone (e.g., from tumor-infiltrating lymphocytes (TILs), peptide-stimulated PBLs from healthy individuals or from immunized human leukocyte antigen (HLA)-transgenic mouse). While the rapid isolation of suitable TCRs for therapy remains a challenge due in part to their high variability (around 40--50 different framework genes for either the α or the β), multiple strategies (mainly using sets of primers for TCR-5′ regions or the rapid-amplification of cDNA ends -- RACE) have been published ([@B1]; [@B18]; [@B15]; [@B156]). Then, these α and β chains are cloned into an expression vector and transduced to previously stimulated normal peripheral T lymphocytes. This enables the reprogramming of the adaptive immune response against antigens of choice based on the specificity of the introduced TCR (reviewed elsewhere; [@B120]; [@B144]; [@B137]). Several clinical studies were elaborated based on this conceptual approach for the treatment of advanced cancer patients: [@B92] demonstrated for the first time that it was possible to transduce normal autologous PBLs from stage IV-metastatic melanoma patients with an MART1-specific TCR and generate large numbers of MART1-specific cells (10^9^--10^10^) to be infused back to the patients. In this Phase I clinical trial, 17 metastatic melanoma patients were treated and 2 of them (12%) demonstrated dramatic tumor regression leading to an objective clinical response. This was followed by a second study in which the same group made use of two high-affinity TCRs against the melanoma antigens MART-1 and gp100 ([@B64]) (including an HLA-A2/gp100~154~-specific murine TCR) in a clinical trial ([@B65]) in which the objective response (OR) rate raised to 30% of the patients treated. Recently, more clinical studies were aimed at exploring the therapeutic potential of TCR-gene transfer to target other cancers than melanoma, using carcinoembryonic (CEA)- ([@B100]), p53- ([@B31]), and NY-ESO- ([@B111]) specific TCRs. The CEA-TCR and p53-TCR were based on murine TCRs isolated in HLA-A2 transgenic hosts and in each study, one patient responded to the treatment. Still, the CEA-TCR clinical trial was limited to only three patients, due to severe inflammatory colitis. Such toxicity emphasizes the possible on-target effects of such therapy. However, [@B111] reported encouraging results using an affinity-enhanced NY-ESO-1-specific TCR. Half (5/11) of the melanoma patients treated as well as 67% of the synovial cell cancer patients underwent an objective clinical response, with two complete responders. Notably, no toxicities were observed in all the patients treated.

Thus far, it has been reported that more than a hundred patients have been treated by the Rosenberg group in the Surgery Branch at NCI using TCR-gene transfer ([@B99]). Nevertheless, several hurdles that may hinder the efficacy of these treatments have been identified along the years and several studies have attempted to solve these issues that include the type of the vector to be used, its configuration, the safety of the procedure, TCR chains mispairing, and the desired functional avidity of the reprogrammed cells. In the present review, we will aim at giving an overview of the recent development in this field and will also elaborate on the development of TCR-gene engineering for conditions other than neoplastic diseases.

MANIPULATING THE FUNCTIONAL AVIDITY OF THE TCR-ENGINEERED CELLS
===============================================================

One of the central questions that pertain to TCR-based gene modifications of lymphocytes is to what extent it is possible for the introduced TCR to reach similar levels of surface expression and functionality as the endogenous one. As T-cell functional avidity is dictated mainly by both TCR affinity and the number of TCR molecules expressed ([@B121]), much efforts has been devoted to improving these biophysical properties in TCR-engineered cells using two important approaches: the improvement of TCR affinity and expression and the enhancement of TCR chain pairing and expression. Based on *in vitro* comparative assays ([@B64]) and the recent solution of the crystal structure ([@B17]) of a highly avid (DMF5) and a medium-avid (DMF4) MART1-specific TCRs, and on the other hand the results obtained in two clinical trials published using these TCRs ([@B92]; [@B65]), it is reasonable to surmise that the use of TCRs that endow T-cells with superior functional avidity might help to improve OR rates \[i.e., 30% OR for the DMF5 ([@B65]) compared to 12% for the DMF4 ([@B92])\]. In addition, TCR affinity increase can assist in augmenting T-cell sensitivity to tumors and in compensating for sub-optimal TCR expression. Such high-affinity TCR should also function in CD8-negative cells such as Th1 or Th17, providing additional support for the anti-tumor response ([@B28]; [@B76]; [@B143]). Several approaches to increase the functional avidity of TCR-engineered cells have been described lately (summarized in **Figure [1](#F1){ref-type="fig"}**).

![**A summary of optimization strategies for TCR expression and pairing.** The naturally expressed/endogenous TCR is depicted in gray and the introduced/exogenous TCR in blue/purple. TM, transmembrane; sc, single chain.](fimmu-03-00186-g001){#F1}

TCR AFFINITY MATURATION
-----------------------

Because most of the tumor antigens are self antigens, the isolation of high-affinity TCR reactive against tumor antigen from human donors can represent a major challenge, since high-avidity CTLs specific for tumor cells may be deleted by negative selection. However, it is possible to increase TCR affinity by mutating selectively amino acids in polymorphic TCR complementarily determining regions -- CDRs ([@B22]). The screening of mutated TCRs using yeast or phage-display libraries can yield affinity improvement up to supra-physiological levels ([@B59]; [@B82]). For example, [@B82] isolated NY-ESO-specific TCR with affinities in the picomolar range. Similarly, a Gag-specific TCR that underwent a 360-fold increase in affinity demonstrated a more efficient control of the spread of HIV virus *in vitro*([@B151]). Nevertheless, such affinity increase can prove detrimental to T-cell function by endowing T-cells with non-specific/self-reactivities ([@B165]) or, paradoxically, by causing defective recognition of low concentrations of antigen ([@B138]). In parallel, some studies demonstrated the benefit of introducing a reduced number of CDR-targeted mutations; [@B110] increased the affinity of several TCR by several fold using an alanine-scan of CDR regions and site-directed mutagenesis of only one to two residues. This approach was used to increase the affinity of two TCRs, a CEA- and an NY-ESO1-specific TCRs, which were subsequently used in recent clinical trials ([@B101]; [@B111]) in which several patients underwent clinical objective tumor regression. Another work recently showed that TCRs seldom express a glycine residue at position 107 in the CDR3β instead of serine. Based on modeling and molecular dynamics simulation, a G107S replacement led to 10--1,000-fold increase in antigen sensitivity in three of four TCRs tested ([@B5]).

ISOLATION OF TCRs FROM HLA-MISMATCHED- OR TRANSGENIC DONORS
-----------------------------------------------------------

High-affinity TCRs could be isolated from HLA-mismatched donors ([@B115]; [@B117]; [@B7]), HLA-transgenic mice ([@B136]) or transgenic mice expressing the human TCR repertoire ([@B81]), as logically, tolerance mechanisms should not influence non-self reactivity, provided the targeted MHC/peptide complex is recognized as foreign. Additionally, several models utilized HLA-A2 transgenic mice to isolate TCRs, which were revealed to display CD8-independent characteristics ([@B128]). We and others showed that such murine TCRs can efficiently function in CD4^+^ cells ([@B28]; [@B76]; [@B65]).

TCR CODON OPTIMIZATION
----------------------

The genetic code bears some degrees of degeneration as a defined amino acid can be encoded by several (synonymous) codons, which are differentially represented in the cell. Moreover, cryptic splicing sites, mRNA secondary structure, and instability motifs can reduce the expression of proteins. Using algorithms to modify the DNA sequence of TCRs "silently," several TCRs have been "codon-optimized" leading to higher expression levels and enhanced reactivity both *in vitro* and *in vivo* ([@B122]; [@B67]).

TCR DEGLYCOSYLATION
-------------------

Based on the fact that TCR glycosylation can reduce TCR expression and favor its internalization ([@B30]), [@B75] demonstrated that the deletion of some of these N-glycosylation sites (4--5 total in the constant domain) from either human or murine TCRs increased the functional avidity of T-cells transduced with these mutated TCRs.

USE OF "STRONG" TCRs
--------------------

It appears that certain TCRs (termed "strong TCRs") can compete better for surface expression when expressed in the presence of various other TCRs ([@B130]; [@B54]). TCR stability is likely to be influenced by protein dynamics and folding as well as interactions between the TCR-variable regions. However, it is unclear what determines the "strength" of a defined TCR *a priori*.

INCORPORATION OF HYDROPHOBIC MUTATIONS IN THE TRANSMEMBRANE REGION
------------------------------------------------------------------

The TCR transmembrane regions contain three positively charged residues that may be associated with the lack of stability of the entire chains ([@B129]). We designed an original approach to selectively improve exogenous TCR stability by increasing the hydrophobic nature of the TCRα transmembrane region. Incorporation of hydrophobic residues at evolutionary-permissive positions resulted in an enhanced surface expression of the TCR chains, leading to an improved cellular avidity and anti-tumor TCR activity ([@B51]).

OPTIMIZATION OF TCR CHAINS PAIRING
----------------------------------

One of the central impediments in the TCR-gene transfer strategy lies with the mispairing of the exogenous α and β TCR chains (α~EX~ and β~EX~) with the naturally expressed endogenous TCR chains (α~NAT~ and β~NAT~; reviewed in detail in [@B48]). Thus, four different αβ dimers can form in the transduced cells: the endogenous TCR (α~NAT~/β~NAT~), the transduced (desired) TCR (α~EX~/β~EX~) as well as two mixed dimers (α~EX~/β~NAT~ and α~NAT~/β~EX~). Since the surface expression of these TCR necessitates for these chains to assembly with a limited number of CD3 molecules, the existence of unproductive forms of TCR leads to reduced levels of the exogenous TCR. Additionally, two reports recently showed that these TCRs mixed heterodimers may engender autoimmunity manifestations and self-reactivity both in a mouse model ([@B11]) and *in vitro* ([@B149]).

Consequently, many groups, including ours, are involved in developing approaches to reduce the mispairing effect as well as to promote the pairing of the exogenous TCR chains. These strategies include the addition of a second disulfide bond ([@B26]; [@B74]), the "murinization" of all or part of the TCR constant regions ([@B132]; [@B27]; [@B152]; [@B139]; [@B14]; [@B131]), the use of a "knob into holes" approach ([@B154]), of chimeric TCR-CD3ζ chain ([@B126]; [@B47]) or of single-chain TCRs ([@B23]; [@B153]; [@B2]) and have been described in details in several reviews ([@B48]; [@B137]; [@B88]). In addition, shRNA sequences can be incorporated into the TCR encoding vector to knock down the expression of the endogenous TCR ([@B97]). Lately, another elegant approach to knock down the endogenous TCR was reported and is based on the use of zinc-finger nucleases (ZFNs) that target the endogenous TCRα and β chains ([@B104]).

CO-EXPRESSION OF CD3 CHAINS
---------------------------

The restricted level of CD3 molecules can represent a bottleneck for TCR expression. [@B3] demonstrated that increasing the expression of CD3 chains (using polycistronic vectors) can boost the functional avidity of TCR-transduced T-cells and their *in vivo* performance.

GENETIC APPROACHES AND TOOLS FOR THE ENGINEERING OF T-CELLS
===========================================================

The genetic modification of T-cells with a TCR necessitates reliable platforms for the transfer of the genetic information. To date, most of the platforms used for TCR-gene transfer, both for research and in clinical settings, were based on γ-retroviral vectors such as the mouse stem cell virus (MSCV) or myeloproliferative sarcoma virus (MPSV; [@B92]; [@B142]). γ-retroviral vectors mediate genome integration of the transgene(s), which enables its long-term expression in the transduced cells. In this type of vectors, the exact cloning position of the transgene relative to *cis*-elements in the retroviral construct appears critical for proper expression of the TCR ([@B37]). Also, retroviral vectors may demonstrate a risk of insertional mutagenesis, which can cause dysregulated gene expression and subsequent malignant transformation ([@B50]). However, it is important to note that all the recent TCR-gene transfer clinical trials were based on the use of MSCV-based retroviral vectors ([@B99]) and that no signs of lymphoproliferative disease were noted in the patients treated. Additionally, a comprehensive body of evidence support the notion that no replicative competent retroviruses (RCR) or adverse events have been observed in a considerable number of clinical trials ([@B10]). Still, primary lymphocyte stimulation is essential when using γ-retroviral vectors and the latter may shift the T-cell phenotype causing some levels of T-cells exhaustion ([@B42]; [@B58]). Interestingly, the TCR transgene expression in patients seems to decrease quite rapidly (1--2 weeks) following adoptive transfer unlike what was observed in *in vitro* conditions, where it can last several weeks ([@B19]). This decrease seems to be associated with lower general transcriptional activity of the transduced T-cells, in a similar way as for the endogenous TCR ([@B150]). However, this situation may be reversed when restimulating transduced cells.

It is also possible to utilize lentiviral platforms ([@B141]; [@B162]; [@B24]; [@B66]) as they may provide the benefit of efficiently transducing non-dividing cells with a safer integration profile ([@B80]) and resistance to silencing ([@B38]). Nonetheless, the use of stimulating factors such as cytokines is required to achieve desirable levels of TCR expression ([@B20]; [@B66]; [@B103]). In mouse settings, a recent comparison of lenti- and retroviral vectors showed that the latter mediated better results in TCR-gene transfer assays ([@B69]).

Non-viral means to engineer T-cells would significantly reduce the need for intensive testing of the viral supernatant, reducing production time. As such, the use of *in vitro*-transcribed RNA molecules introduced by electroporation ([@B118]; [@B168]) or DNA constructs ([@B140]) represents an interesting alternative for the gene modification of lymphocytes, not only for the rapid screening of gene function ([@B14]; [@B6]) but also in potentially therapeutic settings ([@B166]). On the other hand, the rapid disappearance of transgene after a few days ([@B168]) inherent to this transient system represents a major disadvantage of this approach. Another interesting non-viral approach is based on the use of the *Sleeping Beauty* transposon system ([@B61]; [@B60]). In this system that was "resurrected" based on fossil sequences found in the genomes of salmonid fish, the gene(s) of interest are integrated into the genome using a transposase. This system necessitates the concomitant transfer of two nucleic acid polymers, one being the transposon encoding the gene(s) of interest and the other the transposase itself. In the context of TCR-gene transfer, the use of this approach has recently been reported to provide human T-cells with tumor specificity ([@B102]; [@B63]).

Beyond the type of vector to be used, it is important to note that as the TCR is a dimer formed of two chains, TCRα and TCRβ, these have to be expressed simultaneously by the engineered cells. As the separate introduction of both chains in the recipient chains has proven difficult and rather ineffective, several vector designs strategies have been elaborated to facilitate the efficient expression of the TCR dimer (reviewed in [@B142]). The two main strategies that have been utilized clinically rely on the use of either an internal ribosomal entry site (IRES) or a 2A peptide sequence separating the two chains. One of the potential drawbacks related to the use of an IRES sequence is the possibility that the gene downstream of the IRES is expressed at a lesser level ([@B46]; [@B89]). Alternatively, a 2A peptide sequence, which is employed by several viruses such as the picornavirus ([@B135]), provide an effective way to express simultaneously multiple proteins. Indeed, it has been showed that the 2A peptide can promote a ribosomal "skip." We also showed that a furin cleavage site as well as an amino-acid spacer can be added to the 2A sequence to enhance transgene expression ([@B162]). When comparing both approaches (IRES or 2A peptide) it has been showed that the latter may be better for efficient TCR expression ([@B79]).

Though most of the TCR-gene transfer studies are based on αβTCRs targeting an peptide/MHC class I complex, some reports have also made used of other types of receptors to target tumor cells both *in vitro* and*in vivo*: TCR specific for minor antigens ([@B55]; [@B90]), MHC II-restricted TCRs ([@B161]; [@B169]; [@B49]; [@B69]; [@B134]), and γδTCR ([@B85]).

TCRs is generally thought to be restricted to a single epitope (not considering altered peptide ligands). Therefore, the possibility that a single TCR would target multiple cancer epitopes simultaneously would be advantageous. In that regard, an αβTCR targeting originally an HLA-A0201-restricted MAGE-A3 epitope was recently isolated and interestingly, it demonstrated reactivity against multiple MAGE epitopes ([@B21]).

Additionally and beyond our present scope, it is also possible to modify T-cells to express genes other than those encoding a TCR to redirect T-cell function. These include antibody-based chimeric-antigen receptor (CAR) and other genes to modulate the quality of transduced T-cells (reviewed in [@B70]; [@B62]; [@B73]; [@B88]). Another approach for the direction of T-cell specificity was reported lately and is based on bi-specific molecules termed immune-mobilizing monoclonal TCRs against cancer (ImmTACs; [@B83]). These newly developed reagents comprise an scFv specific for CD3 (T-cell binding moiety) and a high-affinity cancer-specific TCR (tumor targeting moiety) and were shown to mediate tumor recognition and killing both *in vitro*and *in vivo* ([@B83]).

WHICH CELL TO ENGINEER?
=======================

One of the basic assumptions when it comes to TCR engineering for cancer treatment is that since malignant cells ought to present their tumor antigens via the MHC class I molecules, the appropriate effector cells to be genetically modified ought to be CD8^+^ T lymphocytes. Nonetheless, due to the complexity of the acquired immune system and the different T-cell functional subsets, recent work has been devoted to the importance of the type/subset of T-cells to be adoptively transferred.

While they represent a minority of the circulating lymphocytes, γδ T-cells have the advantage of expressing TCR chains that apparently do not pair with αβTCR chains ([@B116]). Thus, the use of these cells represents an interesting possibility to prevent the mispairing of the naturally expressed TCR chains with the exogenous one ([@B147]). Bi-specific T-cells represent another possible option (reviewed in [@B86]); for example, virus-specific cells (specific for EBV, CMV or Influenza) can be engineered to express an additional receptor to target tumor cells ([@B114]; [@B95]; [@B105]; [@B146]). The use of these cells may considerably reduce off-target effects as these cells have a defined specificity and can provide protection from latent viruses during the immunosuppressed phase prior to adoptive transfer. In addition, the continuous expression of viral antigens following initial infection (such as in the case of EBV) may provide constant stimulation leading to increased persistence ([@B105]).

We and others have also attempted at modifying precursor cells such as hematopoietic stem cells (HSCs; [@B148]; [@B167]), or more recently induced pluripotent stem cells (iPS; [@B78]), to express a TCR and to be further differentiated into T-cells using, for example, the OP9-DL1 system. Their plasticity, differentiation capability into many T-cell subsets, and the possible increased potential to persist in the host (correlated with clinical response; [@B109]; [@B92]) represent a formidable advantage over peripheral T-cells and it was shown that such modified cells demonstrate anti-tumor function *in vivo* ([@B4]; [@B161]; [@B49]). However, one has to bear in mind that a major drawback lies with their possible transformation induced by retroviral vectors ([@B50]), though the latter might be circumvented using lentiviral- or transposon-based platforms.

Another interesting option is the use of certain subsets of differentiated T-cells. Following activation, naïve T-cells can turn into effector cells, effector memory or central memory cells. T-cell populations derived from the latter were shown to be exquisitely persistent over time, to further differentiate into both effector and central memory *in vivo*, with adequate response to antigenic challenge, both in a macaque model ([@B12]) and more recently for human virus-specific cells in immunodeficient mice ([@B158]). In regard to TCR-transduced cells, these cells generated *ex vivo* exhibit mainly a CD62L^+^/CD45RO^+^ phenotype similar to central memory T-cells ([@B163]). Still, [@B57],[@B58] showed that TCR-transduced naïve T lymphocytes display increased transgene expression and proliferation compared to memory cells. [@B94] also found that Th17-polarized CD4+ T-cells demonstrate enhanced anti-tumor function, resistance to apoptosis and persistence following adoptive transfer with stem-cell like multipotency signature. The role of Th17 cells in mediating tumor regression was also recently highlighted in a study dealing with the identification of tumor antigens able to mediate tumor regression following immunization ([@B106]). Interestingly, [@B43] recently identified a subset of T-cells (CD45RO^--^, CCR7^+^, CD45RA^+^, CD62L^+^, CD27^+^, CD28^+^, and IL-7Rα^+^) that are endowed with both naïve and memory properties which they termed T memory stem cells (T~scm~). This fascinating subset seems more potent in ACT settings than naïve, central, or effector memory T lymphocytes. Despite their rarity, this type of cells can be generated *in vitro* by stimulating naïve T-cells in the presence of TWS119, a Wnt pathway activator ([@B44],[@B43]) and based on their potential, these cells might provide a promising subset to be TCR gene engineered, which would demonstrate increased reactivity and persistence over time in patients.

SAFETY ISSUES
=============

Notwithstanding classical gene therapy-related issues that some of them will be discussed below, manipulating the immune system and often bypassing tolerance mechanisms can generate immune toxicities. Previous works have shown that the transfer of tumor antigen-specific T-cells can cause autoimmune manifestations such as ocular toxicity ([@B98]) or systemic autoimmunity ([@B112]) and this subject has been thoroughly reviewed in [@B8].

Still, one the obvious advantages of the use of TCR-engineered cells in the published clinical trials and pre-clinical studies is their autologous origin, which certainly eases their engraftment and long-term persistence. Nevertheless, the expression of transgenes mainly from xenogenic provenance (e.g., murine TCRs or virus-derived 2A peptides) might trigger immunogenicity. [@B31] showed that a little less than a quarter of the patients administered T-cells expressing fully murine TCRs (specific for a human pMHC complex) indeed developed antibodies directed essentially to the TCR-variable regions. However this response was not associated with the level of transduced cell persistence or response to therapy.

A comprehensive study showed that 9 years following gene modification of T-cells with a retrovirally expressed transgene, these cells demonstrated stable gene expression profiles and phenotype with no evidence of clonal selection ([@B107]). Additionally, it seems so far that no off-target or GVH disorders were observed in patients treated at the Surgery branch (NCI) in seven different TCR-gene transfer clinical protocols (three of which made use of murine TCR that preferentially pair; [@B99]). As quoted above, no replication competent viruses occurrence was observed in hundreds of patients treated with retrovirally engineered T-cells ([@B10]).

Nevertheless, one has to bear in mind the possible risks associated with this kind of gene therapy such as reactivity to normal tissues expressing the targeted antigen ([@B65]; [@B100]), possible newly generated specificities associated with TCR mispairing ([@B11]; [@B149]), and insertional mutagenesis. Several approaches have been developed to readily eliminate engineered T-cells in case such adverse events take place. These include in part the inclusion of suicide genes ([@B91]) such as a inducible Caspase 9 molecular switch ([@B133]; [@B33]; [@B34]) or Herpes Simplex Virus thymidine kinase (HSV-TK; [@B16]) in the vector and subsequent triggering of cellular death using a chemical inducer of dimerization (CID) or Ganciclovir, respectively. It is also possible to deplete *in vivo* TCR-expressing T-cells using antibodies directed against specific tags (such as c-myc or HA), provided the cDNA sequences encoding these peptide tags are added to the 5′-end of the gene(s) encoding the TCR chains ([@B72]). In addition, this particular TCR-tagging strategy saves the need to include an additional (suicide) gene in the vector construct.

BEYOND CANCER: TCR-GENE TRANSFER FOR OTHER DISORDERS
====================================================

The immune system in general, and T-cells in particular, have been shown to be critically involved both in host defense and unfortunately, in immunopathologies ([@B93]). Thus, the genetic modification of T lymphocytes can provide an attractive way to alter or redirect the immune response in order to target pathogens or remedy to certain T cell-linked pathologies (**Table [1](#T1){ref-type="table"}**).

###### 

Use of TCR-gene transfer for non-neoplastic diseases.

  Condition         Disorder/Pathogen             References
  ----------------- ----------------------------- -------------------
  Autoimmunity      Arthritis                     [@B39]
                                                  [@B160]
                    Systemic autoimmune disease   [@B140]
  Viral infection   Cytomegalovirus (CMV)         [@B125]
                    Epstein-Barr virus (EBV)      [@B119]
                                                  [@B52]
                    Hepatitis B virus (HBV)       [@B45]
                    Hepatitis C virus (HCV)       [@B164]
                    Human immunodeficiency        [@B29]
                    virus (HIV)                   [@B145]
                                                  [@B151]
                    Human papilloma virus (HPV)   [@B123], [@B124])
                    Influenza virus               [@B71]
  Microbial         *Mycobacterium*               [@B84]
  infection         *tuberculosis*                

Amongst T-cells, the Treg subset is important for the immunomodulation of self-reactivity, especially in the case of autoimmune disorders. It is possible to generate antigen-specific Tregs by gene transfer and defined T-cells with regulatory activity, in order to treat autoimmune disease. Several groups showed that co-transduction of T-cells with FOXP3 and specific TCR created T regulatory cells that were able to suppress arthritis in different models ([@B39]; [@B160]), for example, by reduction of Th17 cells and decrease of bone destruction ([@B160]). Still in this study, TCR-redirected natural Tregs showed a better therapeutic potential than FOXP3-transduced cells. In addition, redirected regulatory T-cells specific for nucleosome antigen were shown to suppress a systemic autoimmune disease in a mouse model ([@B40]).

TCR-gene transfer approaches could also be implemented for the redirection of T-cell response against HIV. For example, [@B29] showed more than a decade ago that T-cells can be transduced with a GAG-specific TCR and target cells displaying the relevant epitope. Other HIV antigens were also targeted similarly by TCR-transduced T-cells specific for POL. The engineered lymphocytes showed potent inhibitory activity against HIV-1 replication *in vitro* and substantial cytotoxic activity and cytokine production triggered by either epitope-pulsed or infected with HIV-1 target cells (the functional phenotype was similar to those of the parental CTL clone) ([@B145]). Using an affinity-enhanced codon-optimized GAG-specific TCR, [@B151] were able to demonstrate very high level of TCR expression that translated into a high sensitivity to the presence of low levels of cognate epitopes on APCs, including escape mutants.

Additionally, recent studies have focused on the possibility of engineering T-cells to recognize other viral epitopes. For example, a CD8-independent HCV-specific TCR was isolated and conferred reactivity to both CD4 and CD8 T-cells, leading to the recognition of HCV^+^ hepatoma cells ([@B164]). Other reports have exemplified the potential of TCR-gene transfer strategy to target CMV ([@B125]), EBV ([@B119]; [@B52]), HBV ([@B45]), and HPV ([@B123],[@B124]).

Lately, this approach has been extended to bacterial antigens. As adoptive transfer of *Mycobacterium tuberculosis*-specific effector T-cells has been shown to confer immunity to infected recipients ([@B159]; [@B35]), [@B84] aimed at adapting TCR-gene transfer approach to generate anti-bacterial immunity. They isolated *M. tuberculosis* 38-kDa antigen specific HLA class I and class II-restricted TCRs and subsequently minimally murinized their constant regions ([@B14]; [@B131]) to enhance their expression and function. When introduced in CD8^+^ and CD4^+^ T-cells, respectively, these TCRs where shown to trigger specific cytokine secretion by T-cells in co-culture with antigen-pulsed DCs, as well as cell-mediated cytotoxicity (by the CD8^+^ population) ([@B84]).

CONCLUSIONS AND FUTURE DIRECTIONS
=================================

TCR-gene modifications of primary human T-cells have demonstrated over the past decade significant achievements, the most important one being its encouraging translation from bench to bedside. In the past few years, successful gene-therapy studies have renewed hopes with regard to the ability to genetically modify patient cells for therapeutic purposes ([@B68]; [@B127]). Unlike for monogenic diseases, the broader implementation of TCR-gene transfer as a semi-personalized medicine approach would require the isolation and the characterization of multiple TCRs, due to HLA polymorphism and the variety of tumor antigens that would need to be targeted. The nature of the antigen, its exquisite expression by the tumor, but more importantly, its immunogenicity and its capacity to evoke efficient tumor response will be a crucial determinant for the success of this kind of therapy. More needs to be understood about antigen immunodominance and the kinetics and dynamics of tumor antigen expression, even if impressive tumor regressions were observed in patients treated with monospecific engineered T-cells ([@B92]; [@B65]; [@B99]; [@B111]). In this regard, extensive screening of tumor reactive T-cells such as TILs may provide valuable information about the specificity of the anti-tumor T-cell response in cancer patients ([@B9]). Additionally, the functional characterization of the ability of antigens to mediate tumor regression will provide critical insight as to which epitope(s) TCRs should be specific for ([@B106]). Needless to say that the widespread implementation of such "off-the shelf" gene-therapy protocols will benefit from the development of approaches for *in vivo* infection as well as from a better understanding of the cell selection and conditioning process. The combination of newly immunomodulating agents and/or vaccination strategy may improve the clinical response rates ([@B87]). Overall, the ability of redirecting the specificity of T-cells genetically holds great promise for the immunotherapy of cancer and other diseases.
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